News 2024-10-10
Connect with Porton J-STAR at AAPS PharmSci 360 2024 @ Booth 2431
The AAPS PharmSci 360, held from October 20-23, 2024, is an eminent event in the pharmaceutical industry, renowned for its convergence of key players, thought leaders, and innovative companies from across the globe. This year, Porton J-STAR invites you to connect with us at Booth 2431, where we will be exhibiting our end-to-end global CDMO service capabilities across both drug substance and drug product development and manufacturing, and the differentiated advantages these services offer to customers.
We employ advanced technologies and methodologies in our CDMO services. Our participation at AAPS PharmSci 360 reflects our dedication to innovation and excellence. With over 10,000 professionals and numerous exhibitors from various segments of the pharmaceutical industry, this conference is a premier platform for networking, collaboration, and showcasing cutting-edge advancements. It provides an unparalleled opportunity for us to engage with industry peers, explore potential partnerships, and drive forward the growth and innovation of the pharmaceutical sector.
As one of the world's leading CDMO companies, Porton J-STAR will be attending the event. Our expert speakers will deliver advanced technical insights and industry perspectives, offering attendees a deep dive into the latest developments.
For onsite meeting appointments, please contact:business@portonpharma.com.
Others
More
News 2025-03-21
Porton's Near-Term Target Validated by the SBTi
March 20, 2025, Chongqing—Porton Pharma Solutions Ltd. (Porton) announced today that its near-term greenhouse gas emissions reductions targets have been formally validated by the Science Based Targets initiative (SBTi). This milestone not only signifies its strategic breakthrough in climate governance, but also demonstrates that its decarbonization roadmap is aligned with the 1.5°C climate mitigation pathway.
News 2025-03-19
Porton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate T Cell Therapy Development
Cranbury, New Jersey, March 19, 2025 — Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Eureka Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing novel T‑cell therapies for both solid tumors and hematologic malignancies.
